Get the latest crypto news, updates, and reports by subscribing to our free newsletter.
Giấy phép số 4978/GP-TTĐT do Sở Thông tin và Truyền thông Hà Nội cấp ngày 14 tháng 10 năm 2019 / Giấy phép SĐ, BS GP ICP số 2107/GP-TTĐT do Sở TTTT Hà Nội cấp ngày 13/7/2022.
© 2026 Index.vn
Data from last week indicate a shift in capital flows toward a short-term “risk-on” stance, with equity exchange-traded funds (ETFs) drawing strong net inflows globally while money moved away from defensive positioning into risk assets. U.S. equities extend gains amid ceasefire The U.S. stock market continued its upward momentum into…
HeartBeam, Inc. announced the pricing of its underwritten public offering of 12,500,000 shares of common stock, raising total gross proceeds of $10 million before underwriting discounts, commissions, and offering expenses.
The company also granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions.
The offering is expected to close on or about April 16, 2026, subject to customary closing conditions.
HeartBeam said it intends to use the net proceeds from the offering to support commercialization of its FDA-cleared 12-lead synthesized ECG system, advance development of its extended-wear patch and heart attack detection initiatives, further enhance its AI capabilities, and for working capital and general corporate purposes.
The offering is being led by HeartBeam’s first commercial customer, ClearCardio, along with the company’s executive leadership, board members, existing investors, and several fundamental institutional investors.
Titan Partners, a division of American Capital Partners, is acting as the sole bookrunner for the offering.
The offering is being made pursuant to a shelf registration statement on Form S-3/A (File No. 333-293307) previously filed with the U.S. Securities and Exchange Commission on March 13, 2026, and declared effective on March 17, 2026. A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC, and a final prospectus supplement will be filed with the SEC.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company focused on transforming the detection and monitoring of critical cardiac conditions. The company is developing a cable-free device intended to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG.
HeartBeam said its 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2025. The company also reported holding over 20 issued patents related to technology enablement.
The company noted that the release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially. It directed readers to its SEC filings for additional information.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
